A Randomized, Phase II Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

Trial Profile

A Randomized, Phase II Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2017

At a glance

  • Drugs Dociparstat sodium (Primary) ; Cytarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Cantex Pharmaceuticals
  • Most Recent Events

    • 16 Aug 2016 Status changed from planning to recruiting.
    • 19 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top